Invesco Ltd. Cuts Position in Replimune Group, Inc. (NASDAQ:REPL)

Invesco Ltd. cut its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 51.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 88,006 shares of the company's stock after selling 92,952 shares during the period. Invesco Ltd. owned approximately 0.13% of Replimune Group worth $1,066,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Aster Capital Management DIFC Ltd boosted its stake in Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after acquiring an additional 8,183 shares in the last quarter. Sei Investments Co. bought a new position in shares of Replimune Group during the 4th quarter worth about $148,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Replimune Group in the 4th quarter valued at about $150,000. Arizona State Retirement System bought a new stake in Replimune Group in the 4th quarter valued at about $156,000. Finally, Teacher Retirement System of Texas acquired a new position in Replimune Group during the 4th quarter worth approximately $189,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on REPL shares. BMO Capital Markets raised their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, HC Wainwright raised their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $19.43.

Replimune Group Trading Down 4.5 %

REPL traded down $0.34 on Wednesday, hitting $7.16. 2,247,517 shares of the company were exchanged, compared to its average volume of 893,227. The stock has a market capitalization of $551.43 million, a PE ratio of -2.33 and a beta of 0.68. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The firm has a fifty day simple moving average of $9.54 and a two-hundred day simple moving average of $11.54.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). Sell-side analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.